Welcome to the Centeno-Schultz ClinicThe trusted orthopedic stem cell therapy experts.
Established in 2005, we were the first clinic in the world to use your body’s own stem cells to treat orthopedic problems. As the innovators of orthopedic stem cell therapy, our board certified medical doctors have more experience and have treated substantially more patients than any other orthopedic stem cell provider or clinic across the globe. Our expertise is easy to prove too—the Centeno-Schultz doctors are responsible for almost half of the world’s published research and outcome data on orthopedic stem cells.
What makes Centeno-Schultz superior to other stem cell clinics?
Unlike other stem cell clinics, the Centeno Schultz Clinic reinvests 10% of annual revenue into R&D and is home to one of the world’s most sophisticated clinical and lab research facility for stem cells, platelets, and orthobiologics. Our 12,000-foot facility houses a state-of-the-art clinic, including the latest in digital x-ray (fluoroscopy) and ultrasound imaging equipment, a large, ultramodern clean room for cell processing and counting, and a fellowship program where we educate young physicians in interventional orthopedics.
The Nation’s Most Experienced Regenerative Orthopedics Specialists
With two Colorado locations, the Centeno Schultz Clinic is the world headquarters for the International Regenexx Network and home to multiple stem cell injection research teams. We are the top regenerative orthopedic clinic in the United States, with industry-leading experience, published research, specialized interventional orthopedics training, and published outcome data.
More than 100,650 Regenexx® Procedures have been performed since Regenexx pioneered orthopedic stem cell treatments in 2005. Regenexx Procedures are the most advanced orthopedic stem cell procedures in the world.
The published research on Regenexx procedures accounts for approx. 44% of the world’s orthopedic stem cell literature (cumulative n of patients published & treated with bone marrow stem cells as of 1/1/2019)